[July 13, 2011]

Wright Medical Group, Inc. Announces Exclusive Agreement with ArthroCare® Corporation for Foot and Ankle Products

Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company, today announced a supply and distribution agreement with ArthroCare Corporation, a leading company in orthopaedic sports medicine. ArthroCare will supply Wright with products for soft tissue fixation of the foot and ankle based on ArthroCare's market-leading knotless suturing technology.

The agreement with ArthroCare includes a line of tissue fixation devices based on ArthroCare's Opus® knotless suture fixation technology, which Wright will distribute exclusively to foot and ankle surgeons worldwide. ArthroCare's patented Opus® technology allows surgeons to affix tendons and ligaments to bony structures efficiently and reproducibly, without the need to tie knots. ArthroCare's fixation technology is widely used in the rotator cuff repair market and has been used clinically since 2001 in more than 100,000 procedures worldwide.

Bob Fencl, Senior Director of Foot and Ankle Marketing at Wright, commented, "We are extremely pleased to enter this agreement with ArthroCare. Soft tissue repair is a cornerstone of foot and ankle surgery, and this agreement allows Wright to deliver another innovative technology to our customers."

Wright Medical expects to comercialize products through this relationship during the second half of 2011 through its dedicated foot and ankle sales force.

About Wright

Wright Medical Group, Inc. is a global orthopaedic medical device company and a leading provider of surgical solutions for the foot and ankle market. The Company specializes in the design, manufacture and marketing of devices and biologic products for extremity, hip and knee repair and reconstruction. The Company has been in business for 60 years and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit the Company's website at www.wmt.com.

This press release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Such risks and uncertainties include the impact of Wright's settlement of the federal investigation into Wright's consulting arrangements with orthopaedic surgeons relating to its hip and knee products in the United States, including Wright's compliance with a Deferred Prosecution Agreement through September 2011 and a Corporate Integrity Agreement through September 2015, and those risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2010, under the heading, "Risk Factors" and in Item 1A of Part II of our 10-Qs filed during 2011). Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this press release, and we undertake no obligation to update such statements after this date.

[ Back To TMCnet.com's Homepage ]